{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:29Z","timestamp":1790742029612,"version":"4.1.0"},"reference-count":65,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>With the discovery of tyrosine kinase inhibitors (TKIs), overall survival in patients with chronic myeloid leukemia (CML) now approaches that of the general population. While these TKIs have proven to be lifesaving, remaining on them lifelong creates both physical and financial burdens for patients. Recently, multiple trials have begun looking into the efficacy of trialing patients off these TKIs to see if they can sustain treatment-free remission (TFR). TFR eligibility is currently limited to a small population of patients with both robust and sustained responses to TKIs. Currently, for those who attempt a trial of TFR, the average success rates are promising, with anywhere from 38 to 54% of patients experiencing sustained TFR. For those who fail to maintain sustained TFR, safety results to date are reassuring, with almost all patients successfully responding to the re-initiation of TKIs, with death and disease progression being very rare complications. Moving forward, research is being conducted to more accurately risk stratify patients at diagnosis and pair them with optimized upfront treatment regimens aimed at increasing candidacy for the trial of TFR.<\/jats:p>","DOI":"10.3390\/jcm13092567","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T08:49:24Z","timestamp":1714380564000},"page":"2567","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment-Free Remission in Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"13","author":[{"given":"Garrett","family":"Bourne","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Imatinib: The promise of a \u201cmagic bullet\u201d for cancer fulfilled","volume":"92","author":"Henderson","year":"2003","journal-title":"J. Med. Assoc. Ga."},{"key":"ref_2","unstructured":"(2024, February 04). Definition of Philadelphia Chromosome\u2014NCI Dictionary of Cancer Terms\u2014NCI, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/philadelphia-chromosome."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.12.11.1","article-title":"Food and Drug Administration Drug Approval Summary: Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_5","unstructured":"(2024, February 04). Survival Rates for Chronic Myeloid Leukemia. Available online: https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","unstructured":"(2021, September 03). Guidelines Detail. NCCN. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: A systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts","volume":"121","author":"Abboud","year":"2013","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment Value of Second-generation Bcr-Abl1 TKIs Compared With Imatinib to Achieve Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Modelling Study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11899-017-0404-z","article-title":"Chronic Myeloid Leukemia- The Promise of Tyrosine Kinase Inhibitor Discontinuation","volume":"12","author":"Narra","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Saifullah, H.H., and Lucas, C.M. (2021). Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?. Cancers, 13.","DOI":"10.20944\/preprints202106.0609.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: The patient perspective and areas of unmet needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"key":"ref_14","unstructured":"(2024, March 09). National Comprehensive Cancer Network\u2014Home. Available online: https:\/\/www.nccn.org\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): An interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): A single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year Results of the Dasatinib Discontinuation Trial in Patients with Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","article-title":"Feasibility of the imatinib stop study in the Japanese clinical setting: Delightedly overcome CML expert stop TKI trial (DOMEST Trial)","volume":"24","author":"Fujisawa","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: The JALSG-STIM213 study","volume":"107","author":"Takahashi","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): A non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.13430","article-title":"Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation","volume":"109","author":"Kumagai","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","article-title":"Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan","volume":"103","author":"Takahashi","year":"2018","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/blood.V126.23.5152.5152","article-title":"Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML) the Tawam Experience","volume":"126","author":"Alam","year":"2015","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.19269","article-title":"How to improve treatment-free remission eligibility in chronic myeloid leukaemia?","volume":"204","author":"Costa","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e4695659","DOI":"10.1097\/01.HS9.0000967540.46956.59","article-title":"S157: Nilotinib vs. nilotinib + peg-interferon \u03b1lpha induction and nilotinib or peg-interferon \u03b1lpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients. the tiger trial","volume":"7","author":"Hochhaus","year":"2023","journal-title":"HemaSphere"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood-2021-146412","article-title":"Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial","volume":"138","author":"Nicolini","year":"2021","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e34543a6","DOI":"10.1097\/01.HS9.0000967536.34543.a6","article-title":"S156: Frontline asciminib combination in chronic phase chronic myeloid leukemia patients. the fascination trial","volume":"7","author":"Ernst","year":"2023","journal-title":"HemaSphere"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/s41375-020-0805-1","article-title":"Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: The DASCERN randomized study","volume":"34","author":"Cortes","year":"2020","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.HS9.0000843516.08806.86","article-title":"S156: International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission in patients with with chronic myeloid leukemia","volume":"6","author":"Pane","year":"2022","journal-title":"HemaSphere"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1470-2045(22)00406-5","article-title":"Induction\u2013maintenance approach for the chronic phase of chronic myeloid leukaemia (IMPACT-I): A prospective, single-arm, phase 2 study","volume":"23","author":"Cheung","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood-2021-145411","article-title":"First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib","volume":"138","author":"Breccia","year":"2021","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results","volume":"23","author":"Haddad","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1182\/blood-2022-169777","article-title":"Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate\/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial","volume":"140","author":"Abraham","year":"2022","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3904\/kjim.2021.158","article-title":"Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J. Intern. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fonc.2019.00372","article-title":"Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis","volume":"9","author":"Chen","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2020062","DOI":"10.4084\/mjhid.2020.062","article-title":"Prognostic Significance of Transcript-Type BCR\u2014ABL1 in Chronic Myeloid Leukemia","volume":"12","author":"Molica","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Etienne, G., Dulucq, S., Bauduer, F., Adiko, D., Lifermann, F., Dagada, C., Lenoir, C., Schmitt, A., Klein, E., and Madene, S. (2020). Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients. Cancers, 12.","DOI":"10.3390\/cancers12092521"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bjh.16408","article-title":"Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: A systematic review of literature with a meta-analysis of studies over the last ten years","volume":"189","author":"Dulucq","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2018-99-114656","article-title":"Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100817","DOI":"10.1016\/j.neo.2022.100817","article-title":"Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia","volume":"32","author":"Kim","year":"2022","journal-title":"Neoplasia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.V128.22.1887.1887","article-title":"Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs","volume":"128","author":"Matsuki","year":"2016","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2019-123719","article-title":"The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt","volume":"134","author":"Legros","year":"2019","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells","volume":"32","author":"Ross","year":"2018","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hon.2896","article-title":"Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience","volume":"39","author":"Ureshino","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2019.05.007","article-title":"Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation","volume":"19","author":"Kota","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_64","unstructured":"(2024, February 10). Article\u2014Billing and Coding: MolDx: BCR-ABL (A55233), Available online: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/article.aspx?articleid=55233&ver=19&keywordtype=starts&keyword=bcr-abl&bc=0."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jval.2020.05.019","article-title":"Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia","volume":"23","author":"Nguyen","year":"2020","journal-title":"Value Health"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/9\/2567\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:28Z","timestamp":1760106868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/9\/2567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jcm13092567"],"URL":"https:\/\/doi.org\/10.3390\/jcm13092567","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]}}}